Absolute Determination of the 22Na(p,g) Reaction Rate in Novae

Gamma-ray telescopes in orbit around the Earth are searching for evidence of the elusive radionuclide 22Na produced in novae. Previously published uncertainties in the dominant destructive reaction, 22Na(p,g)23Mg, indicated new measurements in the proton energy range of 150 to 300 keV were needed to constrain predictions. We have measured the resonance strengths, energies, and branches directly and absolutely by using protons from the University of Washington accelerator with a specially designed beamline, which included beam rastering and cold vacuum protection of the 22Na implanted targets. The targets, fabricated at TRIUMF-ISAC, displayed minimal degradation over a ~ 20 C bombardment as a result of protective layers. We avoided the need to know the stopping power, and hence the target composition, by extracting resonance strengths from excitation functions integrated over proton energy. Our measurements revealed that resonance strengths for E_p = 213, 288, 454, and 610 keV are stronger by factors of 2.4 to 3.2 than previously reported. Upper limits have been placed on proposed resonances at 198-, 209-, and 232-keV. We have re-evaluated the 22Na(p,g) reaction rate, and our measurements indicate the resonance at 213 keV makes the most significant contribution to 22Na destruction in novae. Hydrodynamic simulations including our rate indicate that the expected abundance of 22Na ejecta from a classical nova is reduced by factors between 1.5 and 2, depending on the mass of the white-dwarf star hosting the nova explosion.Comment: 20 pages, 18 figures; shortened paper, accepted in Phys. Rev.

Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts

Background Late-stage breast cancer preferentially metastasises to bone; despite advances in targeted therapies, this condition remains incurable. The lack of clinically relevant models for studying breast cancer metastasis to a human bone microenvironment has stunted the development of effective treatments for this condition. To address this problem, we have developed humanised mouse models in which breast cancer patient-derived xenografts (PDXs) metastasise to human bone implants with low variability and high frequency. Methods To model the human bone environment, bone discs from femoral heads of patients undergoing hip replacement surgery were implanted subcutaneously into NOD/SCID mice. For metastasis studies, 7 patient-derived xenograft tumours (PDX: BB3RC32, ER+ PR+ HER2−; BB2RC08, ER+ PR+ ER2−; BB6RC37, ER− PR− HER2− and BB6RC39, ER+ PR+ HER2+), MDA-MB-231-luc2, T47D-luc2 or MCF7-Luc2 cells were injected into the 4th mammary ducts and metastases monitored by luciferase imaging and confirmed on histological sections. Bone integrity, viability and vascularisation were assessed by uCT, calcein uptake and histomorphometry. Expression profiling of genes/proteins during different stages of metastasis were assessed by whole genome Affymetrix array, real-time PCR and immunohistochemistry. Importance of IL-1 was confirmed following anakinra treatment. Results Implantation of femoral bone provided a metabolically active, human-specific site for tumour cells to metastasise to. After 4 weeks, bone implants were re-vascularised and demonstrated active bone remodelling (as evidenced by the presence of osteoclasts, osteoblasts and calcein uptake). Restricting bone implants to the use of subchondral bone and introduction of cancer cells via intraductal injection maximised metastasis to human bone implants. MDA-MB-231 cells specifically metastasised to human bone (70% metastases) whereas T47D, MCF7, BB3RC32, BB2RC08, and BB6RC37 cells metastasised to both human bone and mouse bones. Importantly, human bone was the preferred metastatic site especially from ER+ PDX (100% metastasis human bone compared with 20–75% to mouse bone), whereas ER-ve PDX developed metastases in 20% of human and 20% of mouse bone. Breast cancer cells underwent a series of molecular changes as they progressed from primary tumours to bone metastasis including altered expression of IL-1B, IL-1R1, S100A4, CTSK, SPP1 and RANK. Inhibiting IL-1B signalling significantly reduced bone metastasis. Conclusions Our reliable and clinically relevant humanised mouse models provide significant advancements in modelling of breast cancer bone metastasis

The interaction of 11Li with 208Pb

Background: 11Li is one of the most studied halo nuclei. The fusion of 11Li with 208Pb has been the subject of a number of theoretical studies with widely differing predictions, ranging over four orders of magnitude, for the fusion excitation function. Purpose: To measure the excitation function for the 11Li + 208Pb reaction. Methods: A stacked foil/degrader assembly of 208Pb targets was irradiated with a 11Li beam producing center of target beam energies from above barrier to near barrier energies (40 to 29 MeV). The intensity of the 11Li beam (chopped) was 1250 p/s and the beam on-target time was 34 hours. The alpha-decay of the stopped evaporation residues was detected in a alpha-detector array at each beam energy in the beam-off period (the beam was on for <= 5 ns and then off for 170 ns). Results: The 215At evaporation residues were associated with the fusion of 11Li with 208Pb. The 213,214At evaporation residues were formed by the breakup of 11Li into 9Li + 2n, with the 9Li fusing with 208Pb. The 214At evaporation residue appears to result from a "quasi-breakup" process. Conclusions: Most of 11Li + 208Pb interactions lead to breakup with a small fraction (<= 11%) leading to complete fusion.Comment: 25 pages, 11 figure

The 21Na(p,gamma)22Mg Reaction and Oxygen-Neon Novae

The 21Na(p,gamma)22Mg reaction is expected to play an important role in the nucleosynthesis of 22Na in Oxygen-Neon novae. The decay of 22Na leads to the emission of a characteristic 1.275 MeV gamma-ray line. This report provides the first direct measurement of the rate of this reaction using a radioactive 21Na beam, and discusses its astrophysical implications. The energy of the important state was measured to be E$_{c.m.}$= 205.7 $\pm$ 0.5 keV with a resonance strength $\omega\gamma = 1.03\pm0.16_{stat}\pm0.14_{sys}$ meV.Comment: Accepted for publication in Physical Review Letter

12^{12}C+16^{16}O sub-barrier radiative capture cross-section measurements

We have performed a heavy ion radiative capture reaction between two light heavy ions, $^{12}$C and $^{16}$O, leading to $^{28}$Si. The present experiment has been performed below Coulomb barrier energies in order to reduce the phase space and to try to shed light on structural effects. Obtained $\gamma$-spectra display a previously unobserved strong feeding of intermediate states around 11 MeV at these energies. This new decay branch is not fully reproduced by statistical nor semi-statistical decay scenarii and may imply structural effects. Radiative capture cross-sections are extracted from the data.Comment: 4 pages, 7 figures, to appear as proceedings of FUSION 2011 conference at St-Malo, Franc

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer

There is increasing evidence of anti-tumour effects of bisphosphonates from pre-clinical studies, supporting a role for these drugs beyond their traditional use in treatment of cancer-induced bone disease. A range of model systems have been used to investigate the effects of different bisphosphonates on tumour growth, both in bone and at peripheral sites. Most of these studies conclude that bisphosphonates cause a reduction in tumour burden, but that early intervention and the use of high and/or repeated dosing is required. Successful eradication of cancer may only be achievable by targeting the tumour cells directly whilst also modifying the tumour microenvironment. In line with this, bisphosphonates are demonstrated to be particularly effective at reducing breast tumour growth when used in combination with agents that directly target cancer cells. Recent studies have shown that the effects of bisphosphonates on breast tumours are not limited to bone, and that prolonged anti-tumour effects may be achieved following their inclusion in combination therapy. This has opened the field to a new strand of bisphosphonate research, focussed on elucidating their effects on cells and components of the local, regional and distal tumour microenvironment. This review highlights the recent developments in relation to proposed anti-tumour effects of bisphosphonates reported from in vitro and in vivo models, and summarises the data from key breast cancer studies. Evidence for effects on different processes and cell types involved in cancer development and progression is discussed, and the main outstanding issues identified

The ππ\pi\pi interaction in nuclear matter from a study of the π+A→π+π±A′\pi^+ A \to \pi^+ \pi^{\pm} A' reactions

The pion-production reactions $\pi^+ A \to \pi^+\pi^{\pm} A'$ were studied on $^{2}H$, $^{12}C$, $^{40}Ca$, and $^{208}Pb$ nuclei at an incident pion energy of $T_{\pi^{+}}$=283 MeV. Pions were detected in coincidence using the CHAOS spectrometer. The experimental results are reduced to differential cross sections and compared to both theoretical predictions and the reaction phase space. The composite ratio $\cal C$$_{\pi\pi}^A$ between the $\pi^{+}\pi^{\pm}$ invariant masses on nuclei and on the nucleon is also presented. Near the $2m_{\pi}$ threshold pion pairs couple to $(\pi\pi)_{I=J=0}$ when produced in the $\pi^+\to \pi^+\pi^-$ reaction channel. There is a marked near-threshold enhancement of $\cal C$$_{\pi^+\pi^-}^A$ which is consistent with theoretical predictions addressing the partial restoration of chiral symmetry in nuclear matter. Furthermore, the behaviour of $\cal C$$_{\pi^+\pi^-}^A$ is well described when the restoration of chiral symmetry is combined with standard P-wave renormalization of pions in nuclear matter. On the other hand, nuclear matter only weakly influences $\cal C$$_{\pi^+\pi^+}^A$, which displays a flat behaviour throughout the energy range regardless of $A$.Comment: 30 pages, 16 figures, PS format, accepted for publication in Nucl. Phys